The Viscosupplementation Market is inextricably linked to the global demographic shift toward an older society. Osteoarthritis is one of the leading causes of disability worldwide, and with the "silver tsunami" hitting developed nations, the pool of eligible patients is expanding rapidly. This demographic trend ensures a steady and long-term demand for joint lubrication therapies that help maintain an independent lifestyle.

Economic factors also play a role, as healthcare systems look for cost-effective alternatives to expensive and invasive joint replacement surgeries. Viscosupplementation serves as an "interim" therapy that can manage symptoms for years before a patient requires surgery. This bridge therapy is highly valued by healthcare payers and patients who wish to avoid the long recovery times and risks associated with surgical intervention.

Furthermore, the rise in obesity rates globally is contributing to earlier onset of joint wear and tear, pushing younger demographics toward the market. Lifestyle changes and a focus on "active aging" mean that patients are seeking treatments that allow them to continue physical activities despite joint degradation. Consequently, the market is seeing a diversification in product offerings tailored to different stages of joint disease and patient activity levels.

People Also Ask:

• At what stage of osteoarthritis is viscosupplementation most effective?

• Can I walk immediately after a gel injection in my knee?

• How many times can you get viscosupplementation in a lifetime?